SCHEMBL6780474

SCHEMBL6780474

CCC(C(=O)O)C(N)c1cc(Br)c(O)c(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 1/20 0.43
FOLH1 Q04609 1/20 0.38
TSHR P16473 4/20 0.36
HSD17B10 Q99714 3/20 0.36
HIF1A Q16665 2/20 0.36
CYP2C9 P11712 1/20 0.36
ESR1 P03372 1/20 0.36
THRA P10827 2/20 0.33
THRB P10828 2/20 0.33
PTPN1 P18031 1/20 0.33
PPARG P37231 1/20 0.33
AKR1C4 P17516 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
AKR1C1 Q04828 1/20 0.33
TDP1 Q9NUW8 3/20 0.32
CYP3A4 P08684 2/20 0.32
CYP2C19 P33261 1/20 0.32
ALOX15 P16050 2/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6783703 0.98 TTR (0.42) TTRFOLH1TSHRHSD17B10HIF1A
SCHEMBL6779107 0.81 TTR (0.43) TTRTSHRHSD17B10HIF1ACYP2C9
SCHEMBL6774969 0.80 TSHR (0.48) TSHRHSD17B10ALOX15ALDH1A1HPGD
SCHEMBL6778049 0.78 FABP3 (0.43) CRHBPCRHR2
Hydrochloric Acid SCHEMBL6378952 0.77 TPMT (0.39) HSD17B10THRBAKR1C3AKR1C2TDP1
SCHEMBL7356667 0.77 SLC1A1 (0.39) AKR1C3AKR1C2
Hydrochloric Acid SCHEMBL6378948 0.77 TPMT (0.39) HSD17B10THRBAKR1C3AKR1C2TDP1
SCHEMBL2420908 0.77 TSHR (0.44) TTRFOLH1TSHRHSD17B10HIF1A
Hydrochloric Acid SCHEMBL6374293 0.76 GPR139 (0.37) CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL6374289 0.76 GPR139 (0.37) CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed